PE20061338A1 - Combinacion de antagonistas del receptor adrenergico alfa 1 o inhibidores de 5 alfa reductasa con inhibidores de pde 5 para la terapia de hiperplasia benigna de prostata - Google Patents
Combinacion de antagonistas del receptor adrenergico alfa 1 o inhibidores de 5 alfa reductasa con inhibidores de pde 5 para la terapia de hiperplasia benigna de prostataInfo
- Publication number
- PE20061338A1 PE20061338A1 PE2006000383A PE2006000383A PE20061338A1 PE 20061338 A1 PE20061338 A1 PE 20061338A1 PE 2006000383 A PE2006000383 A PE 2006000383A PE 2006000383 A PE2006000383 A PE 2006000383A PE 20061338 A1 PE20061338 A1 PE 20061338A1
- Authority
- PE
- Peru
- Prior art keywords
- alpha
- inhibitors
- pde
- adrenergic receptor
- benign prostate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005016981A DE102005016981A1 (de) | 2005-04-13 | 2005-04-13 | Kombination zur Therapie bei benigner Prostatahyperplasie |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20061338A1 true PE20061338A1 (es) | 2007-01-28 |
Family
ID=36608700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000383A PE20061338A1 (es) | 2005-04-13 | 2006-04-11 | Combinacion de antagonistas del receptor adrenergico alfa 1 o inhibidores de 5 alfa reductasa con inhibidores de pde 5 para la terapia de hiperplasia benigna de prostata |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1888075A1 (de) |
JP (1) | JP2008535877A (de) |
KR (1) | KR20080007252A (de) |
CN (1) | CN101193638A (de) |
AR (1) | AR053575A1 (de) |
AU (1) | AU2006233567A1 (de) |
BR (1) | BRPI0610634A2 (de) |
CA (1) | CA2605224A1 (de) |
CR (1) | CR9427A (de) |
DE (1) | DE102005016981A1 (de) |
DO (1) | DOP2006000074A (de) |
GT (1) | GT200600145A (de) |
IL (1) | IL186604A0 (de) |
MA (1) | MA29683B1 (de) |
MX (1) | MX2007012567A (de) |
PE (1) | PE20061338A1 (de) |
RU (1) | RU2007141518A (de) |
SV (1) | SV2008002477A (de) |
TN (1) | TNSN07385A1 (de) |
TW (1) | TW200716122A (de) |
UY (1) | UY29473A1 (de) |
WO (1) | WO2006108519A1 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US20070093493A1 (en) * | 2005-10-12 | 2007-04-26 | Lilly Icos Llc | Treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
US20080261995A1 (en) * | 2005-12-21 | 2008-10-23 | Pfizer Inc. | Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor |
WO2008005039A1 (en) * | 2006-07-07 | 2008-01-10 | Teva Pharmaceutical Industries Ltd. | Solid compositions comprising tadalafil and at least one carrier |
DE102007028869A1 (de) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
NZ585923A (en) | 2007-12-13 | 2012-09-28 | Vanda Pharmaceuticals Inc | Use of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-benzoic acid for treating a condition that is mediated by a 5-HT2A receptor |
WO2009076663A1 (en) | 2007-12-13 | 2009-06-18 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
US8654746B2 (en) | 2010-04-26 | 2014-02-18 | Intel Corporation | Method, apparatus and system for fast session transfer for multiple frequency band wireless communication |
WO2013123965A1 (en) * | 2012-02-20 | 2013-08-29 | Synthon Bv | A fixed dose pharmaceutical formulation |
CN102727456B (zh) * | 2012-07-03 | 2016-06-22 | 北京科信必成医药科技发展有限公司 | 药物口腔崩解片及其制备方法 |
CN105338970B (zh) * | 2013-06-28 | 2019-07-09 | 韩美药品株式会社 | 包含他达拉非和坦洛新的药物胶囊复合制剂 |
DK3024474T3 (da) | 2013-07-23 | 2022-03-28 | Serenity Pharmaceuticals Llc | Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist |
KR101663238B1 (ko) * | 2013-11-15 | 2016-10-14 | 한미약품 주식회사 | 타다라필 및 암로디핀을 포함하는 복합 고형 제제 |
CN106659690B (zh) * | 2014-06-30 | 2020-08-18 | 韩美药品株式会社 | 包括含有活性成分的膜包衣层的复合制剂 |
WO2016003181A1 (ko) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | 활성성분-함유 필름 코팅층을 포함하는 복합제제 |
WO2016003180A1 (ko) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | 5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법 |
KR20170097045A (ko) * | 2014-11-20 | 2017-08-25 | 알레간 인코포레이티드 | 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물 |
JP2019510071A (ja) * | 2016-03-31 | 2019-04-11 | ハンミ ファーマシューティカルズ カンパニー リミテッド | 安定性及び溶出率が改善されたタダラフィル含有及びタムスロシン含有のカプセル複合製剤 |
KR101835506B1 (ko) * | 2016-10-25 | 2018-03-07 | 주식회사 에스텍파마 | 두타스테리드와 타다라필을 함유하는 속효성 복합정제 |
CN108066347B (zh) * | 2016-11-16 | 2021-02-02 | 深圳万和制药有限公司 | 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物 |
KR101879133B1 (ko) * | 2017-07-11 | 2018-07-17 | (주)동구바이오제약 | 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법 |
TR201715231A2 (tr) * | 2017-10-09 | 2019-04-22 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050042177A1 (en) * | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
-
2005
- 2005-04-13 DE DE102005016981A patent/DE102005016981A1/de not_active Withdrawn
-
2006
- 2006-03-29 DO DO2006000074A patent/DOP2006000074A/es unknown
- 2006-03-31 CA CA002605224A patent/CA2605224A1/en not_active Abandoned
- 2006-03-31 EP EP06723901A patent/EP1888075A1/de not_active Withdrawn
- 2006-03-31 AU AU2006233567A patent/AU2006233567A1/en not_active Abandoned
- 2006-03-31 MX MX2007012567A patent/MX2007012567A/es not_active Application Discontinuation
- 2006-03-31 CN CNA2006800207814A patent/CN101193638A/zh active Pending
- 2006-03-31 KR KR1020077026260A patent/KR20080007252A/ko not_active Application Discontinuation
- 2006-03-31 RU RU2007141518/15A patent/RU2007141518A/ru unknown
- 2006-03-31 WO PCT/EP2006/002941 patent/WO2006108519A1/de active Application Filing
- 2006-03-31 JP JP2008505765A patent/JP2008535877A/ja active Pending
- 2006-03-31 BR BRPI0610634-0A patent/BRPI0610634A2/pt not_active Application Discontinuation
- 2006-04-07 SV SV2006002477A patent/SV2008002477A/es not_active Application Discontinuation
- 2006-04-10 GT GT200600145A patent/GT200600145A/es unknown
- 2006-04-11 PE PE2006000383A patent/PE20061338A1/es not_active Application Discontinuation
- 2006-04-11 AR ARP060101410A patent/AR053575A1/es unknown
- 2006-04-12 TW TW095112920A patent/TW200716122A/zh unknown
- 2006-04-12 UY UY29473A patent/UY29473A1/es not_active Application Discontinuation
-
2007
- 2007-10-09 CR CR9427A patent/CR9427A/es not_active Application Discontinuation
- 2007-10-11 IL IL186604A patent/IL186604A0/en unknown
- 2007-10-11 TN TNP2007000385A patent/TNSN07385A1/en unknown
- 2007-10-29 MA MA30335A patent/MA29683B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006233567A1 (en) | 2006-10-19 |
DOP2006000074A (es) | 2006-10-15 |
SV2008002477A (es) | 2008-02-08 |
TNSN07385A1 (en) | 2009-03-17 |
CR9427A (es) | 2007-12-17 |
MA29683B1 (fr) | 2008-08-01 |
UY29473A1 (es) | 2006-11-30 |
CA2605224A1 (en) | 2006-10-19 |
DE102005016981A1 (de) | 2006-10-19 |
GT200600145A (es) | 2007-04-10 |
JP2008535877A (ja) | 2008-09-04 |
RU2007141518A (ru) | 2009-05-20 |
KR20080007252A (ko) | 2008-01-17 |
MX2007012567A (es) | 2007-12-10 |
IL186604A0 (en) | 2008-01-20 |
EP1888075A1 (de) | 2008-02-20 |
AR053575A1 (es) | 2007-05-09 |
TW200716122A (en) | 2007-05-01 |
WO2006108519A1 (de) | 2006-10-19 |
CN101193638A (zh) | 2008-06-04 |
BRPI0610634A2 (pt) | 2010-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20061338A1 (es) | Combinacion de antagonistas del receptor adrenergico alfa 1 o inhibidores de 5 alfa reductasa con inhibidores de pde 5 para la terapia de hiperplasia benigna de prostata | |
CL2011001536A1 (es) | Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
CR10349A (es) | Tabletas de paracetamol de liberacion rapida | |
AR065809A1 (es) | Formulaciones farmaceuticas que contienen un inhibidor sglt2 | |
CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
CL2010001483A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune. | |
CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
CL2012003053A1 (es) | Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad. | |
CL2007003523A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
CL2008003188A1 (es) | Compuestos derivados de piridina y pirazina; composicion farmaceutica que los comprende;y su uso en el tratamiento o prevencion de tumores sensibles a la inhibicion de enzimas del receptor ax1 y/o c-met. | |
AR052775A1 (es) | Comprimidos bicapa de telmisartan y simvastatina | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
CL2007002167A1 (es) | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. | |
MX2009009552A (es) | Inhibidores de metaloproteasa que contienen una porcion heterociclica. | |
GEP20084485B (en) | Matrix for sustained, invariant and independent release of active compounds | |
CL2008002051A1 (es) | Compuestos derivados de isoxazol-4-metoxi, triazol-4-metoxi o pirazol-4-metoxi, con actividad agonista del receptor x de farnesoide (fxr); composicion farmaceutica que los contiene; y el uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento de dislipidemia y enfermedades relacionadas. | |
CL2009000316A1 (es) | Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos. | |
CL2007002994A1 (es) | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. | |
CL2008001038A1 (es) | Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano | |
CR10277A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
CL2008003595A1 (es) | Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central. | |
ECSP099629A (es) | Composición farmacéutica | |
HK1149717A1 (en) | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases | |
CL2010001361A1 (es) | Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |